Puma Biotechnology
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
Neratinib Chapter
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Workable Strategic Report on Breast Cancer Therapeutics Drugs
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Neratinib Chapter
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
ADAPTING
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
Puma Biotech Surges, Defying Yellen
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Product Pipeline
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
